The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3.
Several cancer drugs intercept the ErbB family receptors EGFR (ErbB-1) and HER2 (ErbB-2). However, the therapeutic value of targeting ErbB-3 has been less clear. A report in this issue of Cancer Cell by Sheng et al. renews hopes that intercepting ErbB-3-mediated autocrine loops bears potential for treatment of ovarian cancer.